FEATURES OF LIPID PANEL DATA IN PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA ASSOCIATED WITH COVID-19 AND ARTERIAL HYPERTENSION WITH DIFFERENT CARDIOVASCULAR RISK
DOI:
https://doi.org/10.32782/2786-9067-2024-27-14Keywords:
community-acquired pneumonia, COVID-19, arterial hypertension, cardiovascular risk, lipid profileAbstract
Objective. The lipid profile in community-acquired pneumonia caused by COVID-19 and arterial hypertension with different cardiovascular risk was analyzed. Materials. For this purpose, a retrospective study of the medical records of 191 patients with community- acquired pneumonia, who had an epidemiological history of SARS-CoV-2 infection with identification of SARS-CoV-2 nucleic acid in swabs from the throat or lower respiratory tract using real-time polymerase chain reaction, was conducted no later than 1 month before admission to inpatient treatment. Patients were divided into three groups depending on the severity of pneumonia, and each group - into two subgroups depending on the presence/absence of hypertension. Blood serum lipid profile indicators were determined using commercially available kits on the Cobas 6000 analyzer. Statistical data processing was performed using the STATISTICA 7.0 computer program. Results. It was established that in patients with community-acquired pneumonia associated with COVID- 19, regardless of the presence/absence of comorbid arterial hypertension, the percentage of patients with dyslipidemia increases as the severity of pneumonia increases. The analysis of lipidogram indicators shows the highest concentration of total cholesterol (TC), LDL, and tryglycerides (TG) in patients with community-acquired pneumonia associated with COVID-19 with presence/absence of hypertension class IV of the risk of fatal outcome in pneumonia. At the same time, it was found that the concentration of TC in patients of the 4th group, LDL and TG in patients of the 2nd and 3rd groups with comorbid hypertension was probably higher compared to such data in patients without hypertension. A statistically significant difference was established in patients with community-acquired pneumonia associated with COVID-19 between the severity of pneumonia and the increase in the concentration of TC, TG with moderate, high and very high cardiovascular risk, as well as LDL in patients with moderate and very high cardiovascular risk. Conclusions. In patients with community-acquired pneumonia associated with COVID-19, there is a statistically significant difference between the severity of cardiovascular risk and the deepening of dyslipidemia according to the indicators of LDL, HDL in the 2nd group and TG in the 3rd group.
References
Begue F., Tanaka S., Mouktadi Z., et al. Altered high-density lipoprotein composition and functions during severe COVID-19. Sci Rep. 2021. № 11(1). Р. 2291. Published 2021. Jan 27. doi:10.1038/s41598-021-81638-1
Chang W.T., Toh H.S., Liao C.T., Yu W.L. Cardiac involvement of COVID‐19: a comprehensive review. Am J Med Sci. 2021. № 361. Р. 14–22.
Elseidy S.A., Awad A.K., Vorla M., Fatima A., Elbadawy M.A., Mandal D., Mohamad T. Cardiovascular complications in the post‐acute COVID‐19 syndrome (PACS). Int J Cardiol Heart Vasc. 2022. № 40. Р. 101012.
Fan J., Wang H., Ye G., et al. Letter to the Editor: Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019. Metabolism. 2020. № 107. Р. 154243.
Feingold K.R. The bidirectional link between HDL and COVID -19 Infections. J Lipid Res 2021. № 62. Р. 100067. https: //doi.org/10.1016/j.jlr.2021.100067
Guan W.J., Liang W.H., Zhao Y., et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020. № 55(5). Р. 2000547. doi:10.1183/13993003.00547-2020
Hu X., Chen D., Wu L., et al. Low Serum Cholesterol Level Among Patients with COVID-19 Infection in Wenzhou, China. Clin Chim Acta. 2020. № 510. Р. 105 – 111.
Khovidhunkit W., Kim M-S., Memon R.A., et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res. 2004. № 45. Р. 1169–1196.
Kim J.A., Montagnani M., Chandrasekran S., Quon M.J. Role of lipotoxicity in endothelial dysfunction. Heart Fail Clin. 2012. № 8. Р. 589–607.
Kimura L.F., Sant'Anna M.B., Andrade S.A., et al. COVID-19 induces proatherogenic alterations in moderate to severe non-comorbid patients: A single-center observational study. Blood Cells Mol Dis. 2021. № 92. Р. 102604.
Kjeldsen S.E. Hypertension and cardiovascular risk: General aspects. Pharmacol Res. 2018. № 129. Р. 95–99. doi:10.1016/j.phrs.2017.11.003
Kumari A., Agarwal Y., Singh S.B., Mahajan S., Sharma V. Correlation of Lipid Profile with Inflammatory Markers among COVID -19 Positive Patients: A Retrospective Study. J Clin of Diagn Res. 2022. № 16. Р. BC19–BC23. https: //doi.org/10.7860/JCDR/2022/55477.16744
Masana L., Correig E., Ibarretxe D., et al. Low HDL and high triglycerides predict COVID-19 severity. Sci Rep. 2021. № 11. Р. 7217. https:// Doi.org/10.1038/s41598-021-86747-5.
McKechnie J.L., Blish C.A. The innate immune system: fighting on the front lines or fanning the flames of COVID-19? Cell Host Microbe. 2020. № 27. Р. 863–869.
Meher G., Bhattacharjya S., Chakraborty H. Membrane cholesterol modulates oligomeric status and peptide-membrane interaction of severe acute respiratory syndrome coronavirus fusion peptide. J Phys Chem B. 2019. № 123. Р. 10654–10662.
Mohammed O., Alemayehu E., Ebrahim E., et al. Atherogenic dyslipidemia and associated risk factors among hypertensive patients of five health facilities in Northeast Ethiopia. PLoS ONE. 2023. № 18(2). Р. e0277185.
Noubiap J.J., Bigna J.J., Nansseu J.R., et al. Prevalence of dyslipidaemia among adults in Africa: a systematic review and meta-analysis. The Lancet Global Health. 2018. № 6(9). Р. e998–1007.
Orkaby A.R. The highs and lows of cholesterol: A paradox of healthy aging? J Am Geriatr Soc. 2020. № 68. Р. 236–237.
Papotti B., Macchi C., Favero C., et al. HDL in COVID-19 Patients: Evidence from an Italian Cross-Sectional Study. J Clin Med. 2021. № 10(24). Р. 5955. Published 2021 Dec 18. doi:10.3390/jcm10245955
Pneumonia in adults: diagnosis and management [Electronic resource]. NICE Clinical Guideline (CG 191). Mode of access: https://www.nice.org.uk/guidance/cg191 (date of access: 30.03.2024). Title from screen.
Rajamäki K., Lappalainen J., Öörni K., et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PloS One. 2010. № 5. Р. e11765.
Ren X., Glende J., Yin J., Schwegmann-Wessels C., Herrler G. Importance of cholesterol for infection of cells by transmissible gastroenteritis virus. Virus Res. 2008. № 137. Р. 220–224.
Serhan C.N. Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014. № 510. Р. 92–101.
Schoene D., Schnekenberg L.G., Pallesen L.P., Barlinn J., Puetz V., Barlinn K., Siepmann T. Pathophysiology of cardiac injury in COVID-19 patients with acute ischaemic stroke: what do we know so far? – a review of the current literature. Life (Basel). 2022. № 12. Р. 12.
Soy M., Keser G., Atagündüz P., Tabak F., Atagündüz I., Kayhan S. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol. 2020. № 39. Р. 2085–2094.
Sun X., Wang T., Cai D., et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. 2020. № 53. Р. 38–42.
Tall A.R., Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol. 2015. № 15. Р. 104–116.
Trinder M., Walley K.R., Boyd J.H., et al. Causal inference for genetically determined levels of high-density lipoprotein cholesterol and risk of infectious disease. Arterioscler Thromb Vasc Biol. 2020. № 40. Р. 267–278.
Varga, Z. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020. № 395. P. 1417–1418.
Wang W., Wang C.Y., Wang S.I., Wei J.C. Long‐term cardiovascular outcomes in COVID‐19 survivors among non‐vaccinated population: a retrospective cohort study from the TriNetX US collaborative networks. EClinicalMedicine. 2022. № 53. Р. 101619.
Williams В., Mancia G., Spiering W. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018. Vol. 39, № 33. P. 3021–3104.
Woodhead, M., Blasi, F., Ewig, S., et al. Woodhead M. Guidelines for the management of adult lower respiratory tract infections full version. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2011. № 17(6). Р. E1–E59.
Wu C., Chen X., Cai Y., et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020. № 180. Р. 934–943.
Xu S, Yang H, Wang J, et al. Clinical Characteristics Among Hypertension Patients with Dislipidemia In Shanghai, China. Value Health. 2014. № 17(7). P. A720. DOI:10.1016/j.jval.2014.08.013
